GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lucid Diagnostics Inc (NAS:LUCD) » Definitions » Equity-to-Asset

Lucid Diagnostics (Lucid Diagnostics) Equity-to-Asset : -0.09 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lucid Diagnostics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lucid Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-2.31 Mil. Lucid Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was $27.27 Mil. Therefore, Lucid Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.09.

The historical rank and industry rank for Lucid Diagnostics's Equity-to-Asset or its related term are showing as below:

LUCD' s Equity-to-Asset Range Over the Past 10 Years
Min: -6.16   Med: -0.09   Max: 0.93
Current: -0.09

During the past 5 years, the highest Equity to Asset Ratio of Lucid Diagnostics was 0.93. The lowest was -6.16. And the median was -0.09.

LUCD's Equity-to-Asset is ranked worse than
92.86% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs LUCD: -0.09

Lucid Diagnostics Equity-to-Asset Historical Data

The historical data trend for Lucid Diagnostics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lucid Diagnostics Equity-to-Asset Chart

Lucid Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-5.13 -6.16 0.93 0.71 -0.09

Lucid Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.51 0.36 0.08 -0.09

Competitive Comparison of Lucid Diagnostics's Equity-to-Asset

For the Medical Devices subindustry, Lucid Diagnostics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lucid Diagnostics's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lucid Diagnostics's Equity-to-Asset falls into.



Lucid Diagnostics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lucid Diagnostics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.311/27.27
=-0.08

Lucid Diagnostics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-2.311/27.27
=-0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lucid Diagnostics  (NAS:LUCD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Lucid Diagnostics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Lucid Diagnostics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lucid Diagnostics (Lucid Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Executives
Stanley Lapidus director 101 HARTWELL AVE., LEXINGTON MA 02421
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Pavmed Inc. 10 percent owner 360 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10017
Lishan Aklog director, officer: Chief Executive Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Dennis M Mcgrath officer: Chief Financial Officer C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Aster Angagaw director 150 PEABODY PLACE, MEMPHIS TN 38103
Jacque J Sokolov director
David F Wurtman officer: Chief Medical Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165

Lucid Diagnostics (Lucid Diagnostics) Headlines

From GuruFocus